NKGen Biotech Announces Administration of First Dose of Troculeucel to Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program
NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural ...
NewscastStudio18h
NEP’s path to IP includes Arkona and Manifold Technology
Arkona technologies GmbH and Manifold technologies GmbH, providers of IP core infrastructure solutions, have announced ...